LAVIPHARM
The Lavipharm Group's adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) from continuing operations for the first nine months of 2024 increased by 21.2% to €9.08 million compared to €7.55 million in the corresponding period of the previous year.
14/11/24 • 19:04
Lavipharm Group's consolidated sales increased in the first half of 2024, the company said in a statement, with its consolidated net profit jumping 248.8% compared to the same period last year.
19/09/24 • 19:07
In the first quarter of 2024, Lavipharm Group's total earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 15.9% to €2.85 million from €2.46 million in the same period in 2023.
23/05/24 • 18:11
Commercialization of the product by Lavipharm is expected to take place upon completion of the relevant marketing authorization transfer, during Q2 of 2024
11/12/23 • 12:47
Lavipharm announces the signing of an asset purchase agreement with Boehringer Ingelheim International GmbH for the acquisition of two analgesic pharmaceutical products, Lonarid N and Lonalgal
01/12/23 • 12:29